Literature DB >> 9808537

Cytokine repertoire during maturation of monocytes to macrophages within spheroids of malignant and non-malignant urothelial cell lines.

A Konur1, M Kreutz, R Knüchel, S W Krause, R Andreesen.   

Abstract

Terminal maturation of human blood monocytes to macrophages (MAC) in vivo is believed to be important for the morphology, antigen expression and functional activity of the resulting MAC population. This process is modulated by the specific tissue micro-environment to which blood monocytes migrate upon leaving the vasculature. Tumor-associated macrophages (TAM) are a special type of MAC, and little is known about the modulating capacity of the tumor environment on monocyte-to-MAC differentiation. By co-culturing 3-dimensional multicellular spheroids (MCS) of the urothelial-bladder-carcinoma cell lines J82 and RT4 with human monocytes/MAC we generated TAM in vitro. For comparison, monocytes/MAC were co-cultured with the non-tumorigenic urothelial cell line HCV29. The effects on monocyte differentiation were analyzed, particularly with respect to cytokine release. Monocyte maturation was modulated within the tumor spheroid dependent upon the tumor cell type. Monocytes co-cultured with MCS of the poorly differentiated J82 carcinoma spontaneously produced high amounts of IL-1beta and IL-6, but only low amounts of TNF-alpha, which could be further increased by the addition of LPS. This cytokine pattern is characteristic for monocytes and remained constant for up to 8 days in J82-MCS co-cultures. However, in RT4-MCS and HCV29-MCS co-cultures, the initial cytokine pattern changed and after 8 days corresponded well to that of MAC differentiated in vitro without tumor contact. In addition to functional parameters, we analyzed the morphology of J82-MCS-TAM and found that they displayed a monocyte-like morphology. Our data indicate that (1) tumor cells can influence monocyte-to-MAC differentiation, giving rise to TAM with monocyte-specific phenotypic properties; and (2) this capacity is dependent on the type of tumor cell.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808537     DOI: 10.1002/(sici)1097-0215(19981123)78:5<648::aid-ijc20>3.0.co;2-n

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Role of soluble factors and three-dimensional culture in in vitro differentiation of intestinal macrophages.

Authors:  Tanja Spoettl; Martin Hausmann; Katrin Menzel; Heidi Piberger; Hans Herfarth; Juergen Schoelmerich; Frauke Bataille; Gerhard Rogler
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

2.  Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer.

Authors:  Marco Erreni; Alberto Mantovani; Paola Allavena
Journal:  Cancer Microenviron       Date:  2010-09-17

3.  Macrophages promote angiogenesis in human breast tumour spheroids in vivo.

Authors:  L Bingle; C E Lewis; K P Corke; M W R Reed; N J Brown
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

Review 4.  From Chemotherapy to Combined Targeted Therapeutics: In Vitro and in Vivo Models to Decipher Intra-tumor Heterogeneity.

Authors:  Guido Gambara; Manuela Gaebler; Ulrich Keilholz; Christian R A Regenbrecht; Alessandra Silvestri
Journal:  Front Pharmacol       Date:  2018-02-14       Impact factor: 5.810

Review 5.  Sarcoma Spheroids and Organoids-Promising Tools in the Era of Personalized Medicine.

Authors:  Gianluca Colella; Flavio Fazioli; Michele Gallo; Annarosaria De Chiara; Gaetano Apice; Carlo Ruosi; Amelia Cimmino; Filomena de Nigris
Journal:  Int J Mol Sci       Date:  2018-02-21       Impact factor: 5.923

6.  CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer.

Authors:  Makito Miyake; Shunta Hori; Yosuke Morizawa; Yoshihiro Tatsumi; Yasushi Nakai; Satoshi Anai; Kazumasa Torimoto; Katsuya Aoki; Nobumichi Tanaka; Keiji Shimada; Noboru Konishi; Michihiro Toritsuka; Toshifumi Kishimoto; Charles J Rosser; Kiyohide Fujimoto
Journal:  Neoplasia       Date:  2016-09-28       Impact factor: 5.715

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.